RxDoctor Payments Data

Andrew Grunwald, MD

Cardiovascular Disease · New Hyde Park, NYNPI 1477635084

Payments from drug & device makers

$6,541in general payments, 2019–2025

Across 298 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$794
  • Merck$698
  • Amgen$656
  • E.r. Squibb & Sons, L.L.C.$652
  • Novo Nordisk$552
  • AstraZeneca$509
  • plus $3K from 28 others

What the payments were for

  • Speaking & faculty fees$210%
  • Food & beverage$6,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,541 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$182,301
Medicare patients
385
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$154,310
Repatha SureclickEvolocumab57$45,192
XareltoRivaroxaban29$38,942
EntrestoSacubitril/Valsartan26$31,693
BrilintaTicagrelor15$19,037
FarxigaDapagliflozin Propanediol13$12,972
OzempicSemaglutide11$10,965
Ezetimibe109$3,909
Metoprolol Succinate218$3,450
Atorvastatin Calcium288$2,795
Amlodipine Besylate281$2,137
Rosuvastatin Calcium121$1,834
Ranolazine ErRanolazine11$1,809
Prasugrel Hcl33$1,561
ClopidogrelClopidogrel Bisulfate100$1,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$316$154,310129 claims
Johnson & JohnsonXarelto$152$38,94229 claims
AstraZenecaBrilinta, Farxiga$509$32,01028 claims
NovartisEntresto$794$31,69326 claims
Novo NordiskOzempic$552$10,96511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →